Area of research
Oncology · Genetics
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Inflammatory Bowel Disease, Gut microbiota and health, and Microscopic Colitis.
Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab
MgFe-LDH-doped GelMA hydrogel scaffold repaired spinal cord injury via immunoregulation and enhancement of neuronal differentiation
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
Photo-powered all-in-one energy harvesting and storage fibers towards low-carbon smart wearables
Phase evolution, thermophysical and mechanical properties of high-entropy (Ce0.2Nd0.2Sm0.2Eu0.2Yb0.2)2Zr2O7 ceramic for advanced thermal barrier coatings
Abstract LB289: Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC).
Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Immunomodulatory Layered Double Hydroxide Nanoparticles Enable Neurogenesis by Targeting Transforming Growth Factor-β Receptor 2
Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis
79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment